^
    2ms
    WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=75, Recruiting, Werewolf Therapeutics, Inc. | Trial primary completion date: Nov 2023 --> Dec 2024
    Trial primary completion date • Metastases
    |
    WTX-330
    over1year
    WTX-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=75, Recruiting, Werewolf Therapeutics, Inc.
    New P1 trial • Metastases
    |
    IL6 (Interleukin 6) • IL2 (Interleukin 2) • IL10 (Interleukin 10) • IL4 (Interleukin 4)
    |
    WTX-330
    over2years
    Conditionally Activated IL-12 or IFNα Indukine™ Molecules Inhibit Syngeneic Lymphoma Tumor Growth in Mice, Induce Anti-Tumor Immune Responses and Are Tolerated in Non-Human Primates (ASH 2021)
    The WTX-330 INDUKINE™ molecule, a wild-type IL-12 pro-drug, contains a half-life extension (HLE) domain to support infrequent dosing and a high affinity anti-IL-12 neutralizing antibody domain to maintain the molecule in its inactive state in the periphery. Similar studies for WTX-613 are on-going. Preclinical data obtained so far for both programs support the continued development and future evaluation of these innovative and differentiated therapies in hematologic malignancies, both as monotherapies and in multiple combinations with standard of care.
    Preclinical
    |
    CD8 (cluster of differentiation 8) • IFNA1 (Interferon Alpha 1) • IFNAR1 (Interferon (alpha, beta and omega) receptor 1)
    |
    JZP898 • WTX-330